FDA Brief

Warning letters Drugs

FDA warning letter to

Drivergent, Inc.

High riskIssued May 1, 2023Posted May 9, 2023Division of Pharmaceutical Quality Operations III

Drivergent's hand sanitizers had acetaldehyde and acetal above allowed limits, FDA says.

What happened

FDA inspected Drivergent's drug manufacturing facility in Fraser, MI, from October 31 to November 3, 2022. FDA laboratory testing of two hand sanitizer lots found acetaldehyde at 211 and 221 ppm and acetal at 578 and 575 ppm, above the United States Pharmacopeia (USP) limit of 10 ppm expressed as acetaldehyde. FDA also cited CGMP (current good manufacturing practice) and misbranding violations and said the firm did not respond to an August 16, 2022 information request or provide corrective actions for the Form FDA 483 (inspection observations).

What FDA found

  1. Two lots of hand sanitizer contained acetaldehyde and acetal above the USP limit, showing that quality assurance was not functioning under CGMP.

    FD&C Act section 501(a)(2)(B); 21 CFR 211.160(b), 211.165
  2. The firm did not test each batch for identity and strength of the active ingredient before release.

    21 CFR 211.165(a)
  3. The firm did not conduct adequate identity tests on each component lot and did not verify suppliers' certificates of analysis.

    21 CFR 211.84(d)(1) and (2)
  4. Paint was peeling from the ceiling and flakes fell onto the floor and the mixing tote in the production area.

    21 CFR 211.58
  5. The quality unit (the group responsible for quality oversight) lacked written responsibilities and failed to oversee vendor qualification, batch release, complaints, training, and other quality duties.

    21 CFR 211.22(a) and (d)
  6. Labels were misleading because they used an FDA-like acronym with 'Made in FDA Registered Facility,' a one-quart container resembled a beverage, and labels lacked a complete domestic address or phone for adverse-event reports.

    FD&C Act sections 502(a), (i)(1), (x); 21 U.S.C. 352(a), (i)(1), (x)

What FDA wants

FDA asks Drivergent to respond in writing within 15 working days describing corrective actions and prevention, and to confirm whether it intends to resume drug manufacturing, notifying FDA before resuming. If it resumes, FDA says to engage a qualified CGMP consultant and perform a six-system audit.

Who should pay attention

  • retailers and distributors selling Drivergent hand sanitizers
  • brands that buy hand sanitizer from contract manufacturers
  • quality teams at OTC drug manufacturers using ethanol or glycerin

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  2. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  3. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  4. Libby Laboratories, Inc.

    FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.

    High risk